Giuliana Grossi

Because unhealthy sleep is associated with multiple conditions and higher risk of mortality, investigators call for further research on the potential to optimize overall sleep health in the US.

Gary Garcia-Molina, PhD, explains precisely how Sleep Number smart bed technology works after conducting multiple sleep studies.

Nonprofit organizations combined efforts to plan a meeting to inform and educate the FDA and key stakeholders about the experience of caregivers and patients with Phelan-McDermid syndrome (PMS).

At the International Pediatric Sleep Association (IPSA) Congress 2022, investigators from Sleep Number presented 2 investigations that utilized its smart bed technology to analyze pediatric sleep behaviors.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

New data from the International Pediatric Sleep Association (IPSA) Congress 2022 used smart bed technology that revealed consistent findings to previous studies.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

Aside from the inability to fulfill the site inspection, there was no other reason for the FDA deferral. The approval of the combination drug candidate's 2 components are still expected.

The Pompe disease community is anticipating the pivotal FDA decision for AT-GAA, a combination therapy for late-onset Pompe disease (LOPD) that has the potential to expand the armamentarium of physicians.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

Depressive disorders are often accompanied by low levels of resilience and research indicates that targeting insomnia symptoms could address the severity of these psychiatric disorders.

The common inherited condition autosomal dominant polycystic kidney disease (ADPKD) remains elusive when presented in primary care due to its nonspecific symptoms.

Investigators are urging for more research on the mechanisms involved with comorbid insomnia and obstructive sleep apnea (OSA) to reduce the mortality risk in patients with both sleep disorders.

Iptacopan has the potential to address an unmet need in PNH by significantly increasing hemoglobin levels in patients who remain anemic, fatigued and dependent on blood transfusions after anti-C5 treatment.

The moisturizer was designed to address concerns regarding the suitability of sunscreens for individuals with skin of color and show the importance of "aesthetic elegance” to increase sunscreen utilization.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.

Top-line data comparing 2 strains of a non-systemically absorbed drug candidate was announced this morning, with SYNB1934 expected to advance to a phase 3 clinical trial.

A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.

Analyses like the Sickle Cell Data Collection (SCDC) have played prominent roles in establishing new SCD clinics, educating health care providers, guiding new research initiatives, and developing state health care policies.